Estrogen receptor modulator review

Bibliography

• JORDAN VC: Antiestrogens and selective estrogen receptor modulators as multi-functional medicines 1. Receptor interactions. J. Med. Chem. (2003) 46(6):883-908.
   PubMed Web of Science ®Google Scholar
• JORDAN VC: Antiestrogens and selective estrogen receptor modulators as multi-functional medicines 2. Clinical considerations and new agents. J. Med. Chem. (2003) 46(7):1081-1111.
   PubMed Web of Science ®Google Scholar
• MILLER CP: SERMs: evolutionary chemistry, revolutionary biology. Curr. Pharm. Des. (2002) 8(23):2089-2111.
   PubMed Web of Science ®Google Scholar
• VEENEMAN GH: Non-steroidal subtype selective estrogens. Curr. Med. Chem. (2005) 12:1077-1136.
   PubMedGoogle Scholar
• KOEHLER KF, HELGUERO LA, HALDOSEN LA, WARNER M, GUSTAFSSON JA: Reflections on the discovery and significance of estrogen receptor β. Endocrine Rev. (2005) 26(3):465-478.
   PubMed Web of Science ®Google Scholar
• GRESE TA, CHO S, FINLEY DR et al.: Structure–activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenozthiophene core of raloxifene. J. Med. Chem. (1997) 40(2):146-167.
   PubMed Web of Science ®Google Scholar
• MILLER CP, KOMM BS: Targeting the estrogen receptor with SERMs. Ann. Rep. Med. Chem. (2001) 36:149-158.
   Google Scholar
• MARTTUNEN MB, CACCIATORE B, HIETANEN P et al.: Prospective study on gynecological effects of two antiestrogens tamoxifen and toremifene in post-menopausal women. Br. J. Cancer (2001) 84(7):897-902.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA (1999) 282:637-645.
   PubMed Web of Science ®Google Scholar
• MARICIC M, ADACHI JD, SARKAR S et al.: Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Intern. Med. (2002) 162:1140-11433.
   PubMed Web of Science ®Google Scholar
• SIRIS E, ADACHI JD, LU Y et al.: Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Osteoporosis Int. (2002) 13:907-913.
   PubMed Web of Science ®Google Scholar
• KESSEL B, NACHTIGALL L, PLOUFFE L et al.: Effect of raloxifene on sexual function in postmenopausal women. Climacteric (2003) 6(3):248-256.
   PubMed Web of Science ®Google Scholar
• GENNARI L: Lasofoxifene Pfizer. Curr. Opin. Investig. Drugs. (2005) 6(10):1067-1078.
   PubMedGoogle Scholar
• ANONYMOUS: Lasofoxifene: CP-336156, CP-336156. Drugs R D (2005) 6(1):56-60.
   PubMedGoogle Scholar
• AP: Tuesday, September 13 ‘Pfizer Receives Letter From FDA Calling Osteoporosis Drug Oporia® Not Approvable’; SCRIP World Pharmaceutical News, 02/21/2006, doc. S00911632.
   Google Scholar
• GRUBER C, GRUBER D: Bazedoxifene Wyeth. Curr. Opin. Investig. Drugs. (2004) 5(10):1086-1093.
   PubMedGoogle Scholar
• MA YL, BRYANT HU, ZENG Q et al.: Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J. Bone. Mineral Research. (2002) 17(12):2256-2264.
   PubMedGoogle Scholar
• BLIZZARD TA, MORGAN JD, CHAN W et al.: Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms. Bioorg. Med. Chem. Lett. (2005) 15(23):5124-5128.
   PubMedGoogle Scholar
• BLIZZARD TA, DININNO F, MORGAN JD et al.: Estrogen receptor ligands. Part 9: dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers. Bioorg. Med. Chem. Lett. (2005) 15(1):107-113.
   PubMed Web of Science ®Google Scholar
• BLIZZARD TA, DININNO F, CHEN HY et al.: Estrogen receptor ligands. Part 13: dihydrobenzoxathiin SERAMs with an optimized antagonist side chain. Bioorg. Med. Chem. Lett. (2005) 15(17):3912-3916.
   PubMedGoogle Scholar
• KIM S, WU JY, BIRZIN ET et al.: Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor modulators. J. Med. Chem. (2004) 47(9):2171-2175.
   PubMed Web of Science ®Google Scholar
• HARRIS HA, KATZENELLENBOGEN JA, KATZENELLENBOGEN BS: Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology (2002) 143(11):4172-4177.
   PubMed Web of Science ®Google Scholar
• GEISER AG, HUMMEL CW, DRAPER MW et al.: A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone and minimal ovarian stimulation. Endocrinology (2005) 146(10):4524-4535.
   PubMed Web of Science ®Google Scholar
• HUMMEL CW, GEISER AG, BRYANT HU et al.: A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. J. Med. Chem. (2005) 48(2):6772-6775.
   PubMedGoogle Scholar
• MOURITS MJ, DE VRIES EG, WILLEMS PH et al.: Ovarian cysts in women receiving tamoxifen for breast cancer. Br. J. Cancer. (1999) 79:1761-1764.
   PubMed Web of Science ®Google Scholar
• LONG GG, COHEN IR, GRIES CL, YOUNG JK, FRANCIS PC, CAPEN CC: Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol. Pathol. (2001) 29(4):403-410.
   PubMedGoogle Scholar
• PLOUFFE L, FACOQ CM: Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynecol. Investig. (2000) 7:S38-S46.
   Google Scholar
• DAVIES GC, HUSTER MWJ, LU Y et al.: Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. (1999) 93:558-565.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, ZAHASKY KM, SLAOAN JA et al.: Tamoxifen-induced hot flushes. Clin. Breast Cancer (2000) 1:52-56.
   PubMedGoogle Scholar
• WATANABE N, AKIHISA I, HISAO M et al.: Discovery and preclinical characterization of (+)-3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1′-indane] -5,5′-diol hydrochloride: A promising nonsteroidal estrogen receptor agonist for hot flush. J. Med. Chem. (2003) 46(19):3961-3964.
   PubMed Web of Science ®Google Scholar
• WALLACE OB, LAUWERS KS, DODGE JA et al.: A selective estrogen receptor modulator (SERM) for the treatment of hot flushes. J. Med Chem. (2006) 49(3):843-846.
   PubMed Web of Science ®Google Scholar
• WILSON TM, HENKE BR, MOMTAHEN TM et al.: 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. (1994) 37(11):1550-1552.
   Google Scholar
• ZHANG J, LABAREE DC, HOCHBERG RB: Nonpolar and short side chain groups at C-11β of estradiol result in antiestrogens. J. Med. Chem. (2005) 48(5):1428-1447.
   PubMedGoogle Scholar
• ZHANG J, LABAREE DC, MOR G, HOCHBERG RB: Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator. J. Clin. Endocrinol. Metab. (2004) 89(7):3527-3535.
   PubMedGoogle Scholar
• SHIAU AK, BARSTAD D, RADEK JT et al.: Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Bio. (2002) 9(5):359-364.
   PubMedGoogle Scholar
• KUIPER GG, ENMARK E, PELTO-HUIKKO M, NILSSON S, GUSTAFSSON J: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93(12):5925-5930.
   PubMed Web of Science ®Google Scholar
• BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389(6652):753-758.
   PubMed Web of Science ®Google Scholar
• HARRIS HA, ALBERT LM, LEATHURBY Y et al.: Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology (2003) 144(10):4241-4249.
   PubMed Web of Science ®Google Scholar
• MALAMAS MS, MANAS ES, MCDEVITT RE et al.: Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J. Med. Chem. (2004) 47(21):5021-5040.
   PubMed Web of Science ®Google Scholar
• MANAS ES, UNWALLA RJ, ZHANG XB et al.: Structure-based design of estrogen receptor-β selective ligands. J. Am. Chem. Soc. (2004) 126(46):15106-15119.
   PubMedGoogle Scholar
• MALAMAS MS, KEITH JC, HARRIS HA: ERB-041: estrogen receptor (ER)β agonist. Treatment of endometriosis. Treatment of rheumatoid arthritis. Drugs Fut. (2005) 30(4):333-336.
   Google Scholar
• HARRIS HA, BRUNER-TRAN KL, ZHANG X, OSTEEN KG, LYTTLE CR: A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum. Reprod. (2005) 20(4):936-941.
   PubMed Web of Science ®Google Scholar
• MEWSHAW RE, EDSALL R, CUIJAN Y et al.: ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity. J. Med. Chem. (2005) 48(12):3953-3979.
   PubMed Web of Science ®Google Scholar
• VU AT, COHN ST, MANAS ES, HARRIS HA, MEWSHAW RE: ERβ ligands. Part 4: synthesis and structure–activity relationships of a series of 2-phenylquinoline derivatives. Bioorg. Med. Chem. Lett. (2005) 15(20):4520-4525.
   PubMed Web of Science ®Google Scholar
• COLLINI MD, KAUFMAN DH, MANAS ES et al.: 7-Substituted 2-phenyl-benzofurans as ERβ selective ligands. Bioorg. Med. Chem. Lett. (2004) 14(19):4925-4929.
   Google Scholar
• YANG C, EDSALL R, HARRIS HA et al.: ERβ ligands. Part 2: synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg. Med. Chem. (2004) 12(10):2553-2570.
   PubMed Web of Science ®Google Scholar
• MILLER CP, COLLINI MD, HARRIS HA: Constrained phytoestrogens and analogues as ERβ selective ligands. Bioorg. Med. Chem. Lett. (2003) 13(14):2399-2403.
   PubMedGoogle Scholar
• MCDEVITT RE, MALAMAS MS, MANAS ES et al.: Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg. Med. Chem. Lett. (2005) 15(12):3137-3142.
   PubMedGoogle Scholar
• HILLISCH A, PETERS O, KOSEMUND D et al.: Dissecting physiology roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol. Endocrinol. (2004) 18(17):1599-1609.
   PubMed Web of Science ®Google Scholar
• BLIZZARD TA, CANDIDO G, MORGAN JD et al.: Androstenediol analogs as ERβ-selective SERMs. Bioorg. Med. Chem. Lett. (2006) 16(4):834-838.
   PubMedGoogle Scholar
• NORMAN BH, RICHARDSON TI, KRISHNAN V et al.: Benzopyrans are selective estrogen receptor beta agonists for use in the treatment of prostatic diseases. Proceedings of the 229th ACS National Meeting. San Diego, CA. USA (2005), MEDI-260.
   Google Scholar
• CHESWORTH R, WESSEL MD, HEYDEN L et al.: Estrogen receptor β-selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg. Med. Chem. Lett. (2005) 15(24):5562-5566.
   PubMedGoogle Scholar
• CHESWORTH R, WESSEL MD, HEYDEN L: Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg. Med. Chem. Lett. (2004) 14(11):2729-2733.
   PubMed Web of Science ®Google Scholar
• STAUFFER SR, HUANG YR, ARON ZD et al.: Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists. Bioorg. Med. Chem. (2001) 9(1):151-161.
   PubMed Web of Science ®Google Scholar
• SUN J, HUANG YR, HARRINGTON WR et al.: Antagonists selective for estrogen receptor. Endocrinology. (2002) 143(3):941-947.
   PubMed Web of Science ®Google Scholar
• DIXIT V, MAK TW: NF-κB signaling. Many roads lead to Madrid. Cell. (2002) 111(5):615-619.
   PubMedGoogle Scholar
• EVANS MJ, HARRIS HA, MILLER CP, KARATHANASIS SK, ADELMAN SJ: Estrogen receptors α and β have similar activities in multiple endothelial cell pathways. Endocrinology. (2002) 143(10):3785-3795.
   PubMedGoogle Scholar
• TYREE CM, ZOU A, ALLEGRETTO EA: 17β-Estradiol inhibits cytokine induction of the human E-selectin promoter. J. Steroid Biochem. Mol. Biol. (2002) 80(3):291-297.
   PubMedGoogle Scholar
• MUKHERJEE TK, NATHAN L, DINH H, REDDY ST, CHAUDHURI G: 17-Epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression. J. Biol. Chem. (2003) 278(13):11746-11752.
   PubMedGoogle Scholar
• CAULIN-GLAZER T, WATSON CA, PARDI R, BENDER JR: Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J. Clin. Invest. (1996) 98(1):36-42.
   PubMedGoogle Scholar
• CUZZOCREA S, MAZZON E, SAUTEBIN L et al.: The protective role of endogenous estrogens in carrageenan-induced lung injury in the rat. Mol. Med. (2001) 7(7):478-487.
   PubMed Web of Science ®Google Scholar
• EVANS MJ, LAI K, SHAW LJ, HARNISH DC, CHADWICK CC: Estrogen receptor α inhibits IL-1β induction of gene expression in the mouse liver. Endocrinology (2002) 143(7):2559-2570.
   PubMedGoogle Scholar
• MIYAMOTO N, MANDAI M, SUZUMA I et al.: Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J. Immunol. (1999) 163(1):374-379.
   PubMed Web of Science ®Google Scholar
• HODGIN JB, MAEDA N: Minireview: estrogen and mouse models of atherosclerosis. Endocrinology (2002) 143(12):4495-4501.
   PubMed Web of Science ®Google Scholar
• JANSSON L, HOLMDAHL R: Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum. (2001) 44(9):2168-2175.
   PubMedGoogle Scholar
• HARNISH DC, ALBERT LM, LEATHURBY Y et al.: Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am. J. Physiol. (2004) 286(1):G118-G125.
   PubMed Web of Science ®Google Scholar
• HARNISH DC: Estrogen receptor ligands in the control of pathogenic inflammation. Curr. Opin. Investig. Drugs. In press.
   Google Scholar
• STEIN B, YANG MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. (1995) 15(9):4971-4979.
   PubMed Web of Science ®Google Scholar
• RAY A, PREFONTAINE KE, RAY P: Down-modulation of interleukin-6 gene expression by l7β-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. (1994) 269(17):12940-12946.
   PubMed Web of Science ®Google Scholar
• RAY P, GHOSH SK, ZHANG DH, RAY A: Repression of interleukin-6 gene expression by 17β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett. (1997) 409(1):79-85.
   PubMed Web of Science ®Google Scholar
• DESHPANDE R, KHALILI H, PERGOLIZZI RG, MICHAEL SD, CHANG MD: Estradiol down-regulates LPS-induced cytokine production and NF-κB activation in murine macrophages. Am. J. Reprod. Immunol. (1997) 38(1):46-54.
   PubMed Web of Science ®Google Scholar
• SUN WH, KELLER ET, STEBLER BS, ERSHLER WB: Estrogen inhibits phorbol ester-induced IκBα transcription and protein degradation. Biochem. Biophys. Res. Commun. (1998) 244(3):691-695.
   PubMedGoogle Scholar
• HARNISH DC, SCICCHITANO MS, ADELMAN SJ, LYTTLE CR, KARATHANASIS SK: The role of CBP in estrogen receptor cross-talk with nuclear factor-κB in HepG2 Cells. Endocrinology (2000) 141(9):3403-3411.
   PubMed Web of Science ®Google Scholar
• SPEIR E, YU ZX, TAKEDA K, FERRANS VJ, CANNON RO: Competition for p300 regulates transcription by estrogen receptors and nuclear factor-κB in human coronary smooth muscle cells. Circ. Res. (2000) 87(11):1006-1011.
   PubMedGoogle Scholar
• STEFFAN RJ, MATELAN E, ASHWELL MA: Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J. Med. Chem. (2004) 47(26):6435-6438.
   PubMed Web of Science ®Google Scholar
• KEITH JC, ALBERT LM, LEATHURBY Y et al.: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis. Arthritis Res. Ther. (2005) 7(3):R427-R438.
   PubMed Web of Science ®Google Scholar
• CHADWICK CC, CHIPPARI CS, MATELAN E et al.: Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc. Natl. Acad. Sci. USA (2005) 102(7):2543-2548.
   PubMed Web of Science ®Google Scholar
• SABATUCCI JP, ASHWELL MA, TRYBULSKI E et al.: Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg. Med. Chem. (2006) 16(4):854-858.
   Google Scholar